Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children’s Oncology Group incorporating nelarabine into front-line therapy

T-cell acute lymphoblastic leukemia (T-ALL), classified by the World Health Organization together with T-cell lymphoblastic lymphoma (T-LBL), is an uncommon disease, comprising only 15% of pediatric, and 25% of adult cases of acute lymphoblastic leukemia (ALL) (1).